Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma

Nature Reviews Urology

Volumn 13, Issue 7, 2016, Pages 420-431

  Carlo, Maria I ^a   Voss, Martin H ^a   Motzer, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ATEZOLIZUMAB; AXITINIB; B7 ANTIGEN; BEVACIZUMAB; BIOLOGICAL MARKER; BMS 936559; CANCER VACCINE; CD134 ANTIGEN; CD86 ANTIGEN; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; EVEROLIMUS; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NIVOLUMAB; OX40 LIGAND; PAZOPANIB; PEMBROLIZUMAB; PEPTIDE FRAGMENT; PROGRAMMED DEATH 1 LIGAND 1; RECOMBINANT INTERLEUKIN 21; SUNITINIB; TUMOR ANTIGEN; VASCULOTROPIN A;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE; DENDRITIC CELL; HEALTH CARE QUALITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; LUNG ALVEOLUS EPITHELIUM CELL; MACROPHAGE; MELANOMA; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; CELL CYCLE CHECKPOINT; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; PROCEDURES; RENAL CELL CARCINOMA;

CARCINOMA, RENAL CELL; CELL CYCLE CHECKPOINTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS;

EID: 84975268061     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2016.103     Document Type: Review

References (119)

1. Coley W. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105, 487-510 (1893
2. McDermott, D. F. Immunotherapy of metastatic renal cell carcinoma. Cancer 115, 2298-2305 (2009
3. Fyfe, G., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin 2 therapy. J. Clin. Oncol. 13, 688-696 (1995
4. Motzer, R. J., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007
5. Hudes, G., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007
6. Motzer, R. J., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008
7. Escudier, B., et al. Bevacizumab plus interferon alfa 2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111 (2015
8. Sternberg C. N., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010
9. Rini, B. I., et al.comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931-1939 (2011
10. Escudier, B., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 1125-134 (2007
11. Postow, M. A., Callahan, M. K., & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974-1982 (2015
12. Brahmer, J. R., et al. Phase I study of single-Agent anti-programmed death 1 (MDX 1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010
13. Topalian, S. L., et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
14. Chen, L. Co inhibitory molecules of the B7 CD28 family in the control of T cell immunity. Nat. Rev. Immunol. 4, 336-347 (2004
15. Appleman, L. J., Chernova, I., Li, L., & Boussiotis, V. A. CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation. Cell Cycle 5, 2123-2129 (2006
16. Kim, H. J. & Cantor, H. CD4 T cell subsets and tumor immunity: the helpful and the not so helpful. Cancer Immunol. Res. 2, 91-98 (2014
17. Mellman, I., Coukos, G., & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011
18. Gabrilovich, D. I., & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009
19. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012
20. Mahoney, K. M., Rennert, P. D., & Freeman, G. J.combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561-584 (2015
21. Chauvin, J. M., et al. TIGIT and PD 1 impair tumor antigen - specific CD8+ T cells in melanoma patients. J. Clin. Invest. 125, 2046-2058 (2015
22. Schwartz, R. H. Costimulation of T lymphocytes: the role of CD28, CTLA 4, and B7/BB1 in interleukin 2 production and immunotherapy. Cell 71, 1065-1068 (1992
23. Krummel, M. F., & Allison, J. P. CD28 and CTLA 4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995
24. Linsley, P. S., et al. CTLA 4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561-569 (1991
25. Krummel, M. F., & Allison, J. P. CTLA 4 engagement inhibits IL 2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183, 2533-2540 (1996
26. Romano, E., et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl Acad. Sci. USA 112, 6140-6145 (2015).
27. Waterhouse, P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla 4. Science 270, 985-988 (1995
28. Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. PD 1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008
29. Fife, B. T., et al. Interactions between PD 1 and PD L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 10, 1185-1192 (2009
30. Rudd, C. E. The reverse stop-signal model for CTLA4 function. Nat. Rev. Immunol. 8, 153-160 (2008
31. Leach, D. R., Krummel, M. F., & Allison, J. P. Enhancement of antitumor immunity by CTLA 4 blockade. Science 271, 1734-1736 (1996
32. Topalian, S. L., Drake, C. G., & Pardoll, D. M. Targeting the PD 1/B7 H1(PD L1) pathway to activate anti-Tumor immunity. Curr. Opin. Immunol. 24, 207-212 (2012
33. Hodi, F. S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
34. Yang, J. C., et al. Ipilimumab (anti CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30, 825-830 (2007
35. Robert, C., Schachter, J., & Long, G. V. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 372-2521 (2015
36. Motzer, R. J., et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J. Clin. Oncol. 33, 1430-1437 (2015
37. Motzer R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373,1803-1813 2015
38. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02210117 (2016
39. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02575222 (2016
40. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/show/NCT01441765 (2016
41. Nguyen, L. T., & Ohashi, P. S. Clinical blockade of PD1 and LAG3 - potential mechanisms of action. Nat. Rev. Immunol. 15, 45-56 (2015
42. Xiao, Y., et al. RGMb is a novel binding partner for PD L2 and its engagement with PD L2 promotes respiratory tolerance. J. Exp. Med. 211, 943-959 (2014
43. Sundar, R., Cho, B. C., Brahmer, J. R., & Soo, R. A. Nivolumab in NSCLC: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 7, 85-96 (2015
44. McDermott, D. F., et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-Term safety, clinical activity, and immune correlates from a phase Ia study. J. Clin. Oncol. 34, 833-842 (2016
45. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT02420821 (2016
46. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02762006 (2016
47. Curran, M. a, Montalvo, W., Yagita, H., & Allison, J. P. PD 1 and CTLA 4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275-4280 (2010
48. Larkin, J., et al.combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015
49. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT01472081 (2016
50. Hammers, H. J., et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) [abstract]. J. Clin. Oncol. 32:5s (Suppl.), 4504 (2014
51. Hammers, H. J., et al. Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) [abstract]. J. Clin. Oncol. 33 (Suppl.), 4516 (2015
52. Hammers, H. J., Plimack, E. R., Sternberg, C. N., McDermott, D. F., & Larkin, J. M. G. CheckMate 214: a phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma [abstract]. J. Clin. Oncol. 33 (Suppl.), TPS4578 (2015
53. Terme, M., et al. Modulation of immunity by antiangiogenic molecules in cancer. Clin. Dev. Immunol. 2012, 492920 (2012
54. Vanneman, M., & Dranoff, G.combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012
55. Desar, I. M. E., et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer 129, 507-512 (2011
56. Yuan, H., et al. Axitinib augments antitumor activity in renal cell carcinoma via STAT3 dependent reversal of myeloid-derived suppressor cell accumulation. Biomed. Pharmacother. 68, 751-756 (2014
57. Du Four, S., et al. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology 4, e998107 (2015
58. Finke, J. H., et al. Sunitinib reverses type 1 immune suppression and decreases T regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14, 6674-6682 (2008
59. Nishino, M., Giobbie-Hurder, A., Ramaiya, N. H., & Hodi, F. S. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J. Immunother. Cancer 2, 40 (2014
60. Hodi, F. S., et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2, 632-642 (2014
61. Rini, B. I., et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117, 758-767 (2011
62. Lieu, C., Bendell, J., Powderly, J. D., Pishvaian, M., & Hochster, S. Safety and efficacy of MPDL3280A (anti PDL1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) with locally advanced or metastatic solid tumors. Ann. Oncol. 25 (Suppl.), iv361-iv372 (2014
63. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT01984242 (2016
64. Amin, A., Plimack, E. R., Infante, J., Ernstoff, B., & Rini, B. I. Nivolumab (anti PD 1; BMS 936558, ONO 4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract]. J. Clin. Oncol. 32:5s (Suppl.), 5010 (2014
65. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT02014636 (2016
66. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT02348008 (2016
67. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT02133742 (2016
68. McDermott, D. F., et al. Survival, durable response, and long-Term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33, 2013-2020 (2015
69. Lipson, E. J., et al. Durable cancer regression off-Treatment and effective reinduction therapy with an anti PD 1 antibody. Clin. Cancer Res. 19, 462-468 (2013
70. Chiou, V. L., & Burotto, M. Pseudoprogression and immune-related response in solid tumors. J. Clin. Oncol. 33, 3541-3543 (2015
71. Wolchok, J. D., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2015
72. Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092-2099 (2015
73. Naidoo, J., et al. Toxicities of the anti PD 1 and anti PD L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375-2391 (2015
74. Johnson, D. B., et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234-240 (2016
75. Lawrence, M. S., et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013
76. Snyder, A., et al. Genetic basis for clinical response to CTLA 4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014
77. Rizvi, N. A., et al. Mutational landscape determines sensitivity to PD 1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015
78. Choueiri, T. K., Fishman, M., Escudier, B., Kim, J. J., & Kluger, H. M. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial [abstract]. J. Clin. Oncol. 32:5s (suppl.), 5012 (2014
79. Choueiri, T. K., Fishman, M., Escudier, B., McDermott, D. F., & Kluger, H. M. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes [abstract]. J. Clin. Oncol. 33 (Suppl.), 4500 (2015
80. Thompson, R. H., et al. Costimulatory B7 H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101, 17174-17179 (2004
81. Thompson, R. H., et al. Costimulatory molecule B7 H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104, 2084-2091 (2005
82. Le, D. T., et al. PD 1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015
83. Choueiri, T. K., et al. PD L1 expression in nonclear-cell renal cell carcinoma. Ann. Oncol. 25, 2178-2184 (2014
84. Geynisman, D. M. Anti-programmed cell death protein 1 (PD 1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur. Urol. 68, 912-914 (2015
85. Melero, I., et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509-524 (2014
86. Pal, S. K., Hu, A., & Figlin, R. A. A new age for vaccine therapy in renal cell carcinoma. Cancer J. 19 365-370 2013
87. Oudard, S., et al A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol. Immunother. 60, 261-271 (2011
88. Southall, P. J., et al. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer 61, 89-95 (1990
89. Amato, R. J., et al. Vaccination of metastatic renal cancer patients with MVA 5T4: a randomized, double-blind, placebo-controlled phase III study. Clin. Cancer Res. 16, 5539-5547 (2010
90. Figlin, R. A. Personalized immunotherapy (AGS 003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma. Expert Opin. Biol. Ther. 15, 1241-1248 (2015
91. Amin, A., et al. Survival with AGS 003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J. Immunother. Cancer 3, 14 (2015
92. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT01582672 (2016
93. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT01265901 (2015
94. Walter, S., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254-1261 (2012
95. Rini, B., et al. Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitnib as first-line therapy for advanced/metastatic RCC [abstract]. Ann. Oncol. 26 (Suppl.), 17LBA (2015
96. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01441765 (2016
97. Kakarla, S., & Gottschalk, S. CAR T cells for solid tumors: armed and ready to go?. Cancer J. 20, 151-155 (2014
98. Bui, M. H. T., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003
99. Lamers, C. H. J., et al. Treatment of metastatic renal cell carcinoma with autologous T lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22 (2006
100. Lamers, C. H., et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on target toxicity. Mol. Ther. 21, 904-912 (2013
101. Steffens, M. G., et al. Targeting of renal cell carcinoma with iodine 131 labeled chimeric monoclonal antibody G250. J. Clin. Oncol. 15, 1529-1537 (1997).
102. Kim, J. S., et al. Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma. Arch. Pharm. Res. 37, 559-566 (2014
103. Liu, L., et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin. Cancer Res. 18, 1751-1759 (2012
104. Wang, D., et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer 14, 251 (2014
105. Westwood, J. A., et al. Three agonist antibodies in combination with high-dose IL 2 eradicate orthotopic kidney cancer in mice. J. Transl Med. 8, 42 (2010
106. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT02179918 (2016
107. Infante, J., Burris, H. a, Ansell, S. M., Nemunaitis, J., & Weiss, G. Immunologic activity of an activating anti CD27 antibody (CDX 1127) in patients (pts) with solid tumors [abstract]. J. Clin. Oncol. 32:5s (Suppl.), 3027 (2014
108. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/show/NCT02386111 (2016
109. Grünwald, V., et al. A phase I study of recombinant human interleukin 21 (rIL 21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). Acta Oncol. 50, 121-126 (2011
110. Bhatia, S., et al. Recombinant interleukin 21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J. Immunother. Cancer 27, 2 (2014
111. Thompson, J. A., et al. Phase I study of recombinant interleukin 21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol. 26, 2034-2039 (2008
112. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02318394 (2016
113. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02132754 (2016
114. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02628574 (2015
115. Sanmamed, M. F., et al. Agonists of co stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin. Oncol. 42, 640-655 (2016
116. Peggs, K. S., Quezada, S. A., & Allison, J. P. Cancer immunotherapy: co stimulatory agonists and co inhibitory antagonists. Clin. Exp. Immunol. 157, 9-19 (2009
117. US National Library of Medicine
118. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02298959 (2016
119. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02493751 (2016).